Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Oneness Biotech Co's enterprise value is $2,108.30 Mil.
Oneness Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $13.27 Mil. Therefore, Oneness Biotech Co's EV-to-EBITDA for today is 158.93.
The historical rank and industry rank for Oneness Biotech Co's EV-to-EBITDA or its related term are showing as below:
LUX:ONEA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -15021.3 Med: -32.59 Max: 946.6
Current: 45.89
During the past 13 years, the highest EV-to-EBITDA of Oneness Biotech Co was 946.60. The lowest was -15021.30. And the median was -32.59.
LUX:ONEA's EV-to-EBITDA is ranked worse than 80.3% of 406
companies
in the Biotechnology industry
Industry Median: 14.4
vs LUX:ONEA: 45.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Oneness Biotech Co (LUX:ONEA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Oneness Biotech Co's PE Ratio (TTM) for today is calculated as:
Oneness Biotech Co's share price for today is $23.60.
Oneness Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Oneness Biotech Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LUX:ONEA vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Oneness Biotech Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oneness Biotech Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oneness Biotech Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Oneness Biotech Co's EV-to-EBITDA falls into.
Oneness Biotech Co's current Enterprise Value is $2,108.30 Mil.
Oneness Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oneness Biotech Co (LUX:ONEA) has a EV-to-EBITDA of 158.93 as of Aug. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Oneness Biotech Co. According to the industry distribution chart, Oneness Biotech Co ranks #326 out of 406 companies in the Biotechnology industry, placing it in the top 80.3%.
Is Oneness Biotech Co's EV-to-EBITDA too high?
Oneness Biotech Co's current EV-to-EBITDA is 158.93. The Biotechnology industry median EV-to-EBITDA is 14.40. Oneness Biotech Co's value of 158.93 is 1003.7% above this industry median. Based on the distribution chart, Oneness Biotech Co ranks #326 out of 406 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oneness Biotech Co has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Oneness Biotech Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oneness Biotech Co ranks #326 out of 406 companies for EV-to-EBITDA. This places Oneness Biotech Co in the lower half of its industry. The industry median EV-to-EBITDA is 14.40. Oneness Biotech Co's value of 158.93 is 1003.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.40, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oneness Biotech Co's current EV-to-EBITDA of 158.93 is 1003.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Oneness Biotech Co. For the Biotechnology industry, the median EV-to-EBITDA is 14.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oneness Biotech Co's current EV-to-EBITDA is 158.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oneness Biotech Co stock overvalued right now?
Oneness Biotech Co (LUX:ONEA) has a current EV-to-EBITDA of 158.93. The stock's GF Value™ is $48.97, compared to a current price of $23.60 — trading 51.8% below its estimated fair value. The current EV-to-EBITDA is 158.93 and 1003.7% above the Biotechnology industry median of 14.40. Oneness Biotech Co's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Oneness Biotech Co (LUX:ONEA), the current EV-to-EBITDA is 158.93 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oneness Biotech Co (LUX:ONEA) Overvalued in 2026?
Based on GuruFocus' analysis, Oneness Biotech Co stock appears to be undervalued.
The current stock price of $23.60 is trading 51.8% below its estimated GF Value™ of $48.97.
Key valuation signals for LUX:ONEA:
EV-to-EBITDA: 158.93
GF Value™: $48.97 vs. price of $23.60 (51.8% below fair value)
Industry Position: 1003.7% above the Biotechnology median (#326 of 406)
No single metric tells the full story. See the LUX:ONEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oneness Biotech Co Ltd is engaged in the research and development of new drugs, the sale of pharmaceutical products and health products, and other related businesses. It focuses on developing drugs for the treatment of chronic skin and immune diseases. The Group's product portfolio comprises FESPIXON cream, for the treatment of diabetic foot ulcers, and Bonvadis, a wound care medical device. It also has various other product candidates in its development pipeline, such as FB825, FB704A, SNS812, SNS851, and others. The Group operates in the following reportable segments: New drug research and development, which derives maximum revenue, and the Agricultural products cultivation and organic food segment.
57GF Score
Get the complete analysis for LUX:ONEA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ONEA has been successfully added to your 
